Johnson & Johnson receives a positive CHMP opinion for Rybrevant® (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations.
This positive CHMP opinion makes amivantamab a new option, and the first fully human EGFR-MET bispecific antibody, in the first-line treatment of this lung cancer.
The recommendation follows data from the phase 3 PAPILLON study, which showed that the combination of amivantamab and chemotherapy significantly improved progression-free survival in adult patients, compared with chemotherapy alone.
The results of the PAPILLON study represent an important advance in the therapeutic field of EGFR exon 20 non-small cell lung cancer, demonstrating a significant improvement in progression-free survival with amivantamab combined with first-line chemotherapy, compared with chemotherapy alone', said study investigator Professor Nicolas Girard, Head of the Medical Oncology Department at the Institut Curie and Professor of Thoracic Oncology and Respiratory Medicine at the Université Paris Saclay (France).
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).